SK280989B6 - Spôsob výroby farmaceutického preparátu obsahujúceho zrážací faktor ix - Google Patents

Spôsob výroby farmaceutického preparátu obsahujúceho zrážací faktor ix Download PDF

Info

Publication number
SK280989B6
SK280989B6 SK1633-98A SK163398A SK280989B6 SK 280989 B6 SK280989 B6 SK 280989B6 SK 163398 A SK163398 A SK 163398A SK 280989 B6 SK280989 B6 SK 280989B6
Authority
SK
Slovakia
Prior art keywords
factor
bound
eluted
subjected
plasma
Prior art date
Application number
SK1633-98A
Other languages
English (en)
Slovak (sk)
Inventor
Yendra Linnau
Maria Sazgary
Original Assignee
Baxter Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Aktiengesellschaft filed Critical Baxter Aktiengesellschaft
Publication of SK280989B6 publication Critical patent/SK280989B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicinal Preparation (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK1633-98A 1991-01-25 1992-01-24 Spôsob výroby farmaceutického preparátu obsahujúceho zrážací faktor ix SK280989B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0016391A AT402261B (de) 1991-01-25 1991-01-25 Komplex enthaltend den gerinnungsfaktor ix

Publications (1)

Publication Number Publication Date
SK280989B6 true SK280989B6 (sk) 2000-10-09

Family

ID=3483232

Family Applications (2)

Application Number Title Priority Date Filing Date
SK1633-98A SK280989B6 (sk) 1991-01-25 1992-01-24 Spôsob výroby farmaceutického preparátu obsahujúceho zrážací faktor ix
SK211-92A SK280130B6 (sk) 1991-01-25 1992-01-24 Komplex zrážacieho faktora ix, spôsob jeho výroby,

Family Applications After (1)

Application Number Title Priority Date Filing Date
SK211-92A SK280130B6 (sk) 1991-01-25 1992-01-24 Komplex zrážacieho faktora ix, spôsob jeho výroby,

Country Status (12)

Country Link
US (2) US5281661A (fr)
EP (1) EP0496725B1 (fr)
JP (2) JP2651307B2 (fr)
AT (2) AT402261B (fr)
CA (1) CA2059979C (fr)
CZ (2) CZ280725B6 (fr)
DE (1) DE59207638D1 (fr)
DK (1) DK0496725T3 (fr)
ES (1) ES2098485T3 (fr)
FI (1) FI100111B (fr)
HU (1) HU212362B (fr)
SK (2) SK280989B6 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671586B2 (en) * 1991-03-01 1996-09-05 Aventis Behring Llc Preparation of factor IX
DE4342132C1 (de) * 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
US5888826A (en) * 1994-06-30 1999-03-30 Dade Behring Inc. Combination reagent holding and test device
DE69523722T2 (de) 1994-06-30 2002-08-01 Dade Behring Inc Bioaktive poröse trennteile
US5602037A (en) * 1994-06-30 1997-02-11 Dade International, Inc. Combination reagent holding and test device
DE19506633A1 (de) * 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US5958716A (en) * 1996-06-06 1999-09-28 Dade Behring Inc. Blood factor assay
WO1999022753A1 (fr) * 1997-11-05 1999-05-14 Yoshitomi Pharmaceutical Industries, Ltd. Preparations a base du cofacteur ii de l'heparine et procede de preparation
JP4855074B2 (ja) * 2003-09-30 2012-01-18 一般財団法人化学及血清療法研究所 高純度血液凝固ｉｘ因子調製物およびその精製方法
WO2006005058A2 (fr) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Conjugues polymere-fraction facteur ix
ES2395544T3 (es) * 2004-12-23 2013-02-13 Novo Nordisk Health Care Ag Reducción del contenido de contaminantes proteínicos en composiciones que comprenden una proteína dependiente de la vitamina K de interés
EP2435474A2 (fr) 2009-05-27 2012-04-04 Baxter International Inc Procédé de production d'une préparation d'immunoglobulines hautement concentrée et à usage sous-cutané
KR101441768B1 (ko) 2009-09-17 2014-09-17 박스터 헬쓰케어 에스에이 히알루로니다아제 및 면역글로불린의 안정한 복합제제, 및 그 사용방법
CA2810734A1 (fr) 2010-09-17 2012-03-22 Baxter International Inc. Stabilisation des immunoglobulines par une formulation aqueuse additionnee d'histidine a un ph faiblement acide a neutre
JP6088435B2 (ja) 2010-12-15 2017-03-01 バクスアルタ ゲーエムベーハー 導電率グラディエントを用いる溶出液収集
US9244073B2 (en) 2011-02-25 2016-01-26 Wellstat Diagnostics, Llc Assays for detecting enzymatic activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2543448A1 (fr) * 1983-04-01 1984-10-05 Rhone Poulenc Spec Chim Procede de fractionnement du plasma
US4820805A (en) * 1983-07-14 1989-04-11 New York Blood Center, Inc. Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US4721572A (en) * 1985-07-12 1988-01-26 Miles Laboratories, Inc. Purfication of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices
EP0229026B1 (fr) * 1986-01-06 1995-11-22 Blood Systems Inc, an Arizona not-for-profit corporation Produit sanguin thérapeutique, procédés et méthodes pour le préparer
JPS63108000A (ja) * 1986-05-15 1988-05-12 Green Cross Corp:The 第８因子の精製方法
US4725673A (en) * 1986-08-29 1988-02-16 Alpha Therapeutic Corporation Plasma fraction purification using silica resin bound to a ligand
ES2045167T5 (es) * 1987-10-23 1996-07-01 Centre Regional De Transfusion Preparacion de concentrado de factor ix humano de elevada pureza y de otras proteinas plasmaticas.
DE3914869C1 (fr) * 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De

Also Published As

Publication number Publication date
HU212362B (en) 1996-06-28
CZ280297B6 (cs) 1995-12-13
CA2059979C (fr) 2003-04-15
US5281661A (en) 1994-01-25
SK280130B6 (sk) 1999-08-06
EP0496725A3 (en) 1993-05-05
EP0496725A2 (fr) 1992-07-29
HU9200225D0 (en) 1992-04-28
DE59207638D1 (de) 1997-01-23
FI920342A (fi) 1992-07-26
ATE146220T1 (de) 1996-12-15
FI920342A0 (fi) 1992-01-24
HUT63863A (en) 1993-10-28
JP2651307B2 (ja) 1997-09-10
DK0496725T3 (da) 1997-06-09
US5409990A (en) 1995-04-25
ATA16391A (de) 1996-08-15
AT402261B (de) 1997-03-25
CZ154794A3 (en) 1996-04-17
JPH04295432A (ja) 1992-10-20
JPH08259449A (ja) 1996-10-08
EP0496725B1 (fr) 1996-12-11
CS21192A3 (en) 1992-08-12
JP2866047B2 (ja) 1999-03-08
FI100111B (fi) 1997-09-30
CA2059979A1 (fr) 1992-07-26
ES2098485T3 (es) 1997-05-01
CZ280725B6 (cs) 1996-04-17

Similar Documents

Publication Publication Date Title
SK280989B6 (sk) Spôsob výroby farmaceutického preparátu obsahujúceho zrážací faktor ix
US6005082A (en) Process for purification of factor VIII
US4687664A (en) Method of inactivating reproducible pathogens
EP0140386B1 (fr) Méthode de purification de LPF-HA
EP0131142A2 (fr) Procédé pour récupérer une protéine de membrane cellulaire
JPH02218699A (ja) 精製されたプロテインａ組成物及びそれらの調製方法
Ogawa et al. Purification and some properties of urokinase
EP0391974B1 (fr) Procédé pour la purification des facteurs coagulants du sang dépendants de la vitamine K
Sakamoto et al. Studies on the interaction between heparin and mouse bone collagenase
SK22695A3 (en) Isolation and purification method of proteins dependent from vitamin k
JPH1059866A (ja) 血液凝固第ｖｉｉ因子及び／もしくは活性化血液凝固第ｖｉｉ因子の製造方法
JP3043558B2 (ja) ヒト活性化プロテインｃ調製物及びその製法
JPH02113893A (ja) 凝固因子２、７、９およびｘの１または２以上を濃縮する方法
Josić et al. Size-exclusion chromatography of plasma proteins with high molecular masses
US5445958A (en) Process for purifying blood clotting factors
JPH1075778A (ja) プロトロンビンおよびトロンビンに結合するペプチド
JP2926728B2 (ja) 蛋白質含有組成物の製造方法
EP0813597B1 (fr) Procede de purification par chromatographie de facteurs de coagulation dependants de la vitamine k
AU627446C (en) Chemical process
KIZUKI et al. Porcine pancreatic prokallikrein. II. Purification and some properties of prokallikrein A
JPH0795894A (ja) リポコルチンの精製方法
Nadano et al. Purification of mammalian ribonuclease using immobilized human ribonuclease inhibitor
Mannhalter 4. Therapy with Plasminogen Concentrates: Preliminary Results and Future Strategies
JP2003096094A (ja) プロテインｓの精製法および高比活性プロテインｓ調製物
CZ2000983A3 (cs) Způsob čištění antithrombinu III